Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Therapeutic Response of Cannabidiol in Rheumatoid Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04911127
Recruitment Status : Recruiting
First Posted : June 2, 2021
Last Update Posted : October 6, 2021
Sponsor:
Information provided by (Responsible Party):
Veena Ranganath, MD, MS, University of California, Los Angeles

Brief Summary:
The study will randomly assign Rheumatoid Arthritis (RA) patients on stable RA therapy to either placebo or cannabidiol (CBD). The overall goal of this proposal is to examine the efficacy and safety of CBD treatment as adjunctive to the medical management of RA patients.

Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Cannabis Drug: 200mg Cannabidiol by capsules twice daily Drug: 400mg Cannabidiol by capsules twice daily Drug: Placebo capsules Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double Blind, Placebo-Controlled Trial to Evaluate the Safety and Tolerability of Cannabidiol (CBD) in Moderate to Severe Rheumatoid Arthritis
Actual Study Start Date : October 5, 2021
Estimated Primary Completion Date : June 10, 2024
Estimated Study Completion Date : June 10, 2025

Resource links provided by the National Library of Medicine

Drug Information available for: Cannabidiol

Arm Intervention/treatment
Placebo Comparator: Placebo
Participants will receive capsules containing medium chain triglyceride (MCT) oil
Drug: Placebo capsules
MCT oil capsules as placebo for CBD

Experimental: 200mg CBD twice daily Drug: 200mg Cannabidiol by capsules twice daily
200mg twice daily via 50mg capsules

Experimental: 400 mg CBD twice daily Drug: 400mg Cannabidiol by capsules twice daily
400mg twice daily via 50mg capsules




Primary Outcome Measures :
  1. Change from Baseline in Disease Activity Score (DAS28/ESR) [ Time Frame: Baseline, 12 Weeks ]
    The DAS28 is a combined index for measuring disease activity in rheumatoid arthritis (RA). The index includes swollen joint counts (SJC) and tender joint counts (TJC), both scored 0-28 (higher scores indicate higher disease activity), as well as acute phase response (APR) determined as erythrocyte sedimentation rate (ESR), and general health (GH), both scored 1-100 (higher scores indicate higher disease activity). DAS28 was calculated according to the following formula: DAS28 equals (=) [0.56 multiplied by (*) the square root (√) of TJC] plus (+) [0.28 * √ of SJC] + (0.70 * the natural logarithm (ln) ESR in millimeters per hour (mm/h)] + [0.014 * GH in mm visual analogue assessment (VAS)]. A negative change from randomization indicated improvement.

  2. Tolerability as assessed by participant attrition [ Time Frame: 12 weeks ]
    Tolerability will be evaluated based on the number of participants that drop out due to treatment emergent adverse events or serious adverse events.


Secondary Outcome Measures :
  1. Change in Power Doppler Synovitis Score (PDUS) [ Time Frame: Baseline, 12 weeks ]
    34 joints will be evaluated using a 0 to 3 point scale for each joint and the sum of these represents PDUS. PDUS ranges from 0 to 102. Scores of 0 indicate the least amount of inflammation of the joint while scores of 3 indicate the most amount of inflammation. A higher value of the total score for PDUS represents more severe disease level.

  2. Change in Grey Scale Synovial Hypertrophy Score (GSUS) [ Time Frame: Baseline, 12 weeks ]
    34 joints will be evaluated using a 0 to 3 point scale for each joint and the sum of these represents GSUS. GSUS ranges from 0 to 102. Scores of 0 indicate the least amount of inflammation of the joint while scores of 3 indicate the most amount of inflammation. A higher value of the total score for GSUS represents more severe disease level.


Other Outcome Measures:
  1. Change in inflammatory cytokine and chemokine concentrations [ Time Frame: Baseline, 12 weeks ]
    Inflammatory cytokines and chemokine concentrations from plasma will be evaluated using multiplex cytokine array.

  2. Change in white blood cell (WBC) subset percentages [ Time Frame: Baseline, 12 weeks ]
    WBC subset percentages will be assessed via flow cytometry.

  3. Change in Clinical Disease Activity Index (CDAI) [ Time Frame: Baseline, 12 weeks ]
    CDAI was derived as the sum of the following: tender joint count (TJC), swollen joint count (SJC), participant global assessment (PGA) of disease activity, and physician assessment of disease activity. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 millimeters (mm) and rounded to the nearest centimeter (cm) on a visual analog scale (VAS), where higher scores indicate greater perceived disease activity. The total CDAI score range is 0-76, where higher scores indicate increased disease activity.

  4. Change in Health Assessment Questionnaire - Disability Index (HAQ-DI) [ Time Frame: Baseline, 12 weeks ]
    The HAQ-DI is a patient-reported assessment of physical function that includes 20 items in eight categories representing a comprehensive set of functional activities, including dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Patients are asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst), with a higher score representing a high-dependency disability.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Meet the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 Classification Criteria for Rheumatoid Arthritis
  • Disease activity score (DAS28) >= 3.2
  • Age >= 18
  • Stable RA therapy for 12 weeks prior to baseline
  • Power Doppler Score >= 5 (for the PDUS 34 joint score)
  • Must use at least one highly effective method of contraception
  • Written informed consent

Exclusion Criteria:

  • Prior exposure to cannabis <= 28 days prior to baseline
  • Current diagnosed substance use disorders (including Alcohol Use Disorder)
  • Moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment
  • Chronic infections
  • >10mg of prednisone daily use
  • Daily use of central nervous system (CNS) depressant medications (e.g. sedatives, hypnotics [zolpidem, temazepam, alprazolam, lorazepam, diphenhydramine etc.])
  • Women who are pregnant, planning to become pregnant, or breast feeding
  • Sexually active subjects and their partners who are of childbearing potential (ie, neither surgically sterile nor postmenopausal) and not agreeing to use adequate contraception
  • Deemed unsafe by the investigator
  • History of an allergic reaction or adverse reaction to cannabis is exclusionary.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04911127


Contacts
Layout table for location contacts
Contact: Nicolette Morris, BS 310-825-9956 NTMorris@mednet.ucla.edu

Locations
Layout table for location information
United States, California
UCLA David Geffen School of Medicine, Division of Rheumatology Recruiting
Los Angeles, California, United States, 90095
Contact: Nicolette Morris    310-825-9956      
Principal Investigator: Veena K Ranganath, M.D.         
Principal Investigator: Ziva Cooper, PhD         
Sponsors and Collaborators
University of California, Los Angeles
Investigators
Layout table for investigator information
Principal Investigator: Ziva Cooper, PhD University of California, Los Angeles
Principal Investigator: Veena Ranganath, MD, MS University of California, Los Angeles
Layout table for additonal information
Responsible Party: Veena Ranganath, MD, MS, Principal Investigator, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT04911127    
Other Study ID Numbers: 19-01551
P64-01-003 ( Other Grant/Funding Number: CMCR )
First Posted: June 2, 2021    Key Record Dates
Last Update Posted: October 6, 2021
Last Verified: October 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Cannabidiol
Anticonvulsants